• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Anteris Technologies Global Corp.

    4/8/25 3:14:41 PM ET
    $AVR
    Industrial Specialties
    Health Care
    Get the next $AVR alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Anteris Technologies Global Corp.

    (Name of Issuer)


    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)


    03675P102

    (CUSIP Number)


    03/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    03675P102


    1Names of Reporting Persons

    Sio Capital Management, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    3,464,965.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    3,464,965.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,464,965.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.62 %
    12Type of Reporting Person (See Instructions)

    IA

    Comment for Type of Reporting Person:  1 As of March 31, 2025, Sio Capital Management, LLC beneficially owned 3,464,965 shares of Common Stock with shared voting power and shared dispositive power. 2 Based on 36,023,796 shares of common stock outstanding, as of March 12, 2025, as provided in the Form 10-K of the Issuer filed on March 12, 2025.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Anteris Technologies Global Corp.
    (b)Address of issuer's principal executive offices:

    860 Blue Gentian Road, Suite 340, Eagan, MINNESOTA, 55121
    Item 2. 
    (a)Name of person filing:

    This Statement is filed on behalf of Sio Capital Management, LLC (the "Reporting Person" or "Sio") Sio is a registered investment adviser to certain affiliated funds that directly hold the shares of Common Stock to which this statement relates for the benefit of their respective investors, and in such capacity Sio has voting and dispositive power over such shares.
    (b)Address or principal business office or, if none, residence:

    600 Third Avenue, 2nd Floor New York, New York 10016
    (c)Citizenship:

    Sio is a Delaware limited liability company.
    (d)Title of class of securities:

    Common Stock, par value $0.0001 per share
    (e)CUSIP No.:

    03675P102
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    3,464,965
    (b)Percent of class:

    9.62%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    3,464,965 - Refer to footnote 3

     (iii) Sole power to dispose or to direct the disposition of:

    0

     (iv) Shared power to dispose or to direct the disposition of:

    3,464,965 - Refer to footnote 3 3 Sio and Sio GP, LLC (the "GP") act as investment advisor and general partner, respectively, to various clients that are the record owners of the Common Stock reported on this Schedule 13G. Because Sio's investment discretion with respect to such clients is subject to oversight by the GP, the GP may be deemed to be the beneficial owner of the Common Stock of the Issuer owned by such clients. In addition, both Sio and the GP are controlled by Michael Castor. As such, he may be deemed to control the voting and dispositive decisions with respect to, and therefore be the beneficial owner of, the shares of Common Stock reported on this Schedule 13G. Neither the filing of this Schedule 13G nor any of its contents shall be deemed to constitute an admission by the GP or Michael Castor that such person is the beneficial owner of any of the equity securities referred to herein for purposes of Section 13(d) of the Exchange Act, or for any other purpose, and such beneficial ownership is expressly disclaimed.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Sio Capital Management, LLC
     
    Signature:/s/ Jin W. Lee
    Name/Title:Chief Compliance Officer
    Date:04/04/2025
    Get the next $AVR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AVR

    DatePrice TargetRatingAnalyst
    1/8/2025$20.00Buy
    Lake Street
    1/7/2025$15.00Buy
    TD Cowen
    1/7/2025$9.00Overweight
    Cantor Fitzgerald
    1/7/2025$22.00Overweight
    Barclays
    More analyst ratings

    $AVR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Anteris Appoints David Roberts and Gregory Moss to its Board of Directors

      MINNEAPOLIS and BRISBANE, Australia, June 09, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ:AVR, ASX: AVR)) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced the appointments of Mr. David Roberts and Mr. Gregory Moss to its Board of Directors. The Company also announced the resignation of Dr. Wenyi Gu from the Board upon completion of his term as an Australia-based non-executive director. "On behalf of the management team and Board, I am delighted to welcome David and Gregory to the Company" commented John Seaberg, Chairman o

      6/9/25 10:52:06 PM ET
      $AVR
      $LMAT
      Industrial Specialties
      Health Care
      Medical/Dental Instruments
    • Anteris Announces Results for the First Quarter of 2025

      MINNEAPOLIS and BRISBANE, Australia, May 13, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ:AVR, ASX: AVR)) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today reported financial results for the quarter ended March 31, 2025, and provided a corporate update. First Quarter 2025 Highlights Investigational Device Exemption ("IDE") for the DurAVR® THV's global, pivotal clinical trial (the "PARADIGM Trial"), submitted to the FDA during the First QuarterScale up for commencement of the PARADIGM Trial ongoing – including expanding the Clinical S

      5/13/25 5:45:28 PM ET
      $AVR
      Industrial Specialties
      Health Care
    • Anteris Technologies Reaches Clinical Milestone: 100 patients treated with DurAVR® THV

      MINNEAPOLIS and BRISBANE, Australia, March 31, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris® or the Company) (NASDAQ:AVR, ASX: AVR)) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices, announces a significant milestone in our mission to restore heart valve patients to healthy function. Our first in class, biomimetic DurAVR® Transcatheter Heart Valve (THV) has now been used to treat over 100 patients worldwide, marking a major achievement in our goal to revolutionize cardiac care in patients affected by severe aortic stenosis. Highlights: Over 100 patients successfully treated with the DurAVR® THV,

      3/31/25 7:15:40 AM ET
      $AVR
      Industrial Specialties
      Health Care

    $AVR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Moss Gregory S.

      3 - Anteris Technologies Global Corp. (0002011514) (Issuer)

      6/10/25 6:01:58 AM ET
      $AVR
      Industrial Specialties
      Health Care
    • SEC Form 3 filed by new insider Roberts David B

      3 - Anteris Technologies Global Corp. (0002011514) (Issuer)

      6/10/25 6:01:52 AM ET
      $AVR
      Industrial Specialties
      Health Care
    • Amendment: Director Seaberg John D exercised 40,000 shares at a strike of $7.13 and covered exercise/tax liability with 36,148 shares (SEC Form 4)

      4/A - Anteris Technologies Global Corp. (0002011514) (Issuer)

      3/21/25 9:30:47 AM ET
      $AVR
      Industrial Specialties
      Health Care

    $AVR
    Leadership Updates

    Live Leadership Updates

    See more
    • Anteris Appoints David Roberts and Gregory Moss to its Board of Directors

      MINNEAPOLIS and BRISBANE, Australia, June 09, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ:AVR, ASX: AVR)) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced the appointments of Mr. David Roberts and Mr. Gregory Moss to its Board of Directors. The Company also announced the resignation of Dr. Wenyi Gu from the Board upon completion of his term as an Australia-based non-executive director. "On behalf of the management team and Board, I am delighted to welcome David and Gregory to the Company" commented John Seaberg, Chairman o

      6/9/25 10:52:06 PM ET
      $AVR
      $LMAT
      Industrial Specialties
      Health Care
      Medical/Dental Instruments

    $AVR
    SEC Filings

    See more
    • Anteris Technologies Global Corp. filed SEC Form 8-K: Leadership Update

      8-K - Anteris Technologies Global Corp. (0002011514) (Filer)

      6/9/25 7:00:37 AM ET
      $AVR
      Industrial Specialties
      Health Care
    • SEC Form 10-Q filed by Anteris Technologies Global Corp.

      10-Q - Anteris Technologies Global Corp. (0002011514) (Filer)

      5/13/25 5:22:58 PM ET
      $AVR
      Industrial Specialties
      Health Care
    • Amendment: SEC Form 10-K/A filed by Anteris Technologies Global Corp.

      10-K/A - Anteris Technologies Global Corp. (0002011514) (Filer)

      4/29/25 4:34:06 PM ET
      $AVR
      Industrial Specialties
      Health Care

    $AVR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Lake Street initiated coverage on Anteris Technologies Global Corp. with a new price target

      Lake Street initiated coverage of Anteris Technologies Global Corp. with a rating of Buy and set a new price target of $20.00

      1/8/25 8:52:46 AM ET
      $AVR
      Industrial Specialties
      Health Care
    • TD Cowen initiated coverage on Anteris Technologies Global Corp. with a new price target

      TD Cowen initiated coverage of Anteris Technologies Global Corp. with a rating of Buy and set a new price target of $15.00

      1/7/25 9:02:46 AM ET
      $AVR
      Industrial Specialties
      Health Care
    • Cantor Fitzgerald initiated coverage on Anteris Technologies Global Corp. with a new price target

      Cantor Fitzgerald initiated coverage of Anteris Technologies Global Corp. with a rating of Overweight and set a new price target of $9.00

      1/7/25 9:00:55 AM ET
      $AVR
      Industrial Specialties
      Health Care